Drug Delivery Congress 2017

22 Mar - 23 Mar

Applications for Speaker Positions for 2017 Open

 

Prefilled syringes (PFS) constitute one of the fastest growing segments of the injectable drug delivery device market.  The administration of therapeutic drugs via injection is an indespensable delivery method for numerous drugs critical to patient health and well-being. A prefilled syringe is defined as a single-dose packet of vaccine to which a needle has been fixed by the manufacturer.  Typically metal and glass have been common in the past, however there has been a shift towards plastic and disposable syringes, so the needle is protected and cannot be reused (prefilled disposable systems).

 Estimates show that the global prefilled syringes market , is likely to reach sales of  6.9 billion by 2018, growing at a compound annual growth rate of 13.8% from 2012 to 2018 . Many examples of drugs packed into prefilled syringes are vaccines, blood stimulants, therapeutic proteins, erythoprotein.

The pharmaceutical market promises high potential for prefilled syringes, however production costs are high and manufacturing is complex.  Industrial pressure arising concerning pharmacovigilance and reducing cost suggest there are still challenges to overcome.

Why you should attend this conference:

  • Understand current market dynamics: prospects for the future
  • Analyse manufacturing options ready to fill vs bulk syringes
  • Explore approaches to ensure drug identity, potency and sterility
  • Utilise strategies to ensure quality and safety of prefilled syringes
  • Ensure pharmacovigilance practices 
  • Investigate compatibility issues : avoiding changes in product quality
  • Overcome regulatory and technical hurdles
  • Discover novel prefilled syringe technology
  •  

Day 1

09:30 Registration and refreshments 

10:00 Opening address from the chair 

10:10 Vaccine manufacturing- strategies for the future
- Vaccine market dynamics, a world in change
- New approaches: development and deployment of innovative solutions in vaccine manufacturing
- LEAN in manufacturing, maximizing the output of a facility
- Vaccine manufacturing strategies, from a rigid approach to implementation of flexible technology
- A vision for the future: distributed flexible manufacturing 

Paul von Hoegen, Managing Director , Eurracine

11:00 HIV Vaccine Design & Development

-  HIV Vaccine and Design
- Collaboration for AIDS Vaccine Discovery (CAVD)
- Adenovirus/AAV/Lentivirus vectors 

Dr Takis Athanasopoulos, Lecturer in Molecular Biotechnology, University of Wolverhampton

11:30 Morning refreshments 
 

11:50  Immunogenicity testing using viral pseudotypes

- Design and construction of pseudotypes
- Pseudotypes as serological antigens 
- Immunogenicity testing usung pseudotypes

Nigel Temperton Senior Lecturer, University of Kent

12:30  A unique partnership for product development 

- Vaccine clinical trials sub-Saharan Africa
- Poverty related and neglected infectious diseases
-  Pharma industry & clinical trials

Dr Lara Padya, Director of North- North Cooperation, EDCTP

13:10 Networking lunch 

14:30 Fast track development of manufacturing processesfor recombinant vaccine proteins produced using microbial systems 

- Rapid selection of an optimal expression system and early definition of the upstream production process
- Exploiting pre-optimised platform approaches to purification to quickly define and establish the manufacturing process for bulk API
- Reducing time-lines to move to clinical development 

Anthony Lockett, Senior Director, Retroscreen 

15:10 Mucosal Vaccination to C. difficile Infection

- TBC
- TBC
- TBC

TBC


15:50 Afternoon refreshments 

16:10 Collaborative vaccine partnering
- Strategic alliances shaping the vaccine industry
- Biotech and pharma approaches to strategic alliances
- Case studies- what do partners want and need? 

16:50 Outsourcing production and ensuring GMP and GLP 

17:30 Closing remarks from the chair 

17:40 Networking drinks, Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2


Day 2:

09:30 Registration and refreshments 

10:00 Opening address from the chair 

10:10 Universal influenza vaccines : challenges and hurdles

- Ideal properties of a universal vaccine
- Live attenuated flu vaccine a case study
- Challenges faced by universal vaccines in the clinic 

Helen Bright, Senior Scientist Virology, Astrazeneca

10:50 Developing MDCK cell-culture derived vaccines 

- Developing a cell-based platform for influenza vaccines
- Drivers of immunogenicity and cross protection in animals
- Clinical trial strategy and first data in humans- safety plus pre-clinical and manufacturing processes

Elke Smits, Liason Officer, Centre for Medical Innovation 

11:30 Morning refreshments 

11:50 The transition of a company and product from development to commercialisation 

- Defining the road-map from product development to market entry
- Key business and process decisions to be made along the way
- Identification and management of the transition in:
- Process: from development to routine
- People: changes in required experience and training
- Systems: QA and QC oversight and control
- Structure: Management responsibility 

 Prof Martin Scholz, CSO , Leukocare​ 

12:30 Human Specific Vaccines based on the game changing S-TIR technology platform for therapeutic treatment of severe allergic diseases as well as cancer


- Human Specific Vaccines
- Severe Allergic Diseases
- Oncology

 Geert C.Mudde, Founder and CSO, S-Target Therapeutics GmbH 

13:10 Networking lunch 

14:30 Biosafety testing for Vaccine Industry

-  Regulatory approaches to safety testing
- Novel Cell substrates - testing approaches
- Technology advances for vaccines

Dr Donna  McMutrie, Principle Scientist, Bioreliance


15:10 Challenges in vaccine research in the UK and their significance for International Research 

- How does Infonetica enable effective research management? 
- what solutions are being developed?
- where are the major challenges faced? 

Mel Singh, Account Manager, Infonetica 

15:50 Afternoon refreshments 

16:10 Influenza vaccine production capacity indeveloping countries 

- Growing importance of vaccine manufacturers in developing countries in ensuring access to vaccines
- Initiatives to achieve a more equitable influenza vaccine manufacturing capacity at the global level
- Supportive role of OECD-based vaccinology institutions in this process 

Jerry Sadoff, Head of Early Development, Crucell 

16:50 BRICs- capabilities and advantages in a global market 

- The technological expansion and innovation of emerging suppliers in the international vaccine market
- Movement of production away from U.S. and Europe to Brazil, India and China
- How intellectual property protection affects access to vaccines in developing countries 

17:30 Chair's closing remarks 

17:40 End of conference

Jean-Rene Authelin
Global Head of Pharmaceutical Engineering 
Sanofi
 
Douglas Ball
Researcher Fellow
Pfizer

 

Tiffany Mcintyre
Human Factors Engineer,
Eli Lilly


Yasser Nashed- Samuel
Principle Scientist
Amgen


Chris Muenzer
Drug Delivery Device Engineer
Roche


Irene Cecchini
Researcher, Physio-chemical chracterization Lab 
Merck


Ed Israelski
Program Manager
Abbott Labs


Dennis Jenke
Distinguished Scientist
Baxter Healthcare

 
Aarti Gadh
Principal Scientist
GSK


Kiran Singh
Associate Director
Sandoz Pharmaceuticals


Li-Chun Tsou
Global Device Technical Director, Astrazeneca


Mark Tsai
Pincipal Engineer, Drug Delivery, Johnson & Johnson 

Hanspeter Heiniger
Head of External Quality Combination Products
Roche

 
Joely Gardner
Chief User Researcher
Human Factors Research

 


Scott Arra
Device Technology Lead, Respiratory, Injectables,
and Topical Delivery Systems, North America, GSK


Philippe Bourhis
Technical Director
Fareva


Shem Fischer
Medical Manager, Contract Manufacturing
Oratech


Kerstin Walke
Head Global Pharmaceutical Development
Boehringer Ingelheim


Ed Israelski
Director Human Factors
AbbVie


Edwin Harmon
Director of Manufacturing Operations
Genzyme

 
Diane Paskiet
Faculty Member PQRI Extractables and Leachables
West Pharmaceutical Services


Mike Ronk
Principal Scientist
Amgen


Nan Lin
Manager Drug Product Technology
Regeneron


Ross Allen
Associate Senior Consultant Engineer, Eli Lilly and Company


Stephen Brych
 Principal Scientist
 Amgen


Doug Kiehl
Team Leader - Spectroscopy, Raw Materials and Extractables & Leachables
 Eli Lilly and Company


Gopi Vudathala
Head, Regulatory Affairs CMC & Compliance
GSK Vaccines


Jonathan Amaya Hodges
 Manager, Device Systems Quality
 Biogen

 
Srini Sridharan
 Director, Innovation & Drug Delivery
 Bristol-Myers Squibb

 
John Smith
 Director, Global Regulatory Affairs
 Allergan

 

 

Workshop

Sponsors

 

Media Partners

PharmaVOICE magazine provides commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 25,000 BPA-qualified subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.

SelectScience.net is the leading online product and application publication for laboratory scientists featuring the latest news, application articles, videos, product directory and product reviews. Membership is fast, free and provides access to all of the SelectScience services. SelectScience.tv is a unique video news channel for laboratory application and product information.

 

 

PharmiWeb.com is the leading jobs and news portal for the pharmaceutical, biotech and life sciences sector. Constantly updated with the latest events, features, news and thousands of jobs from all the leading employers in the sector. PharmiWeb.com is brought to you by innovative online publisher and e-business solutions provider, PharmiWeb Solutions.

 

Genetic Engineering & Biotechnology News (GEN)  is the most authoritative and widely read biotechnology news publication in the world.  Published 21 times a year, GEN's unique news and technology content  focus includes  the entire  bioproduct life cycle from early-stage R&D to applied  research and bioprocess through to commercialization. GENis  the only publication that  provides  the full  range of the biotechnology market coverage  in areas such as omics, drug and biomarker discovery, bioprocessing, clinical research, molecular diagnostics, and biobusiness.  For a free subscription, go to http://www.genengnews.com/subscriptions.aspx

 

 

Life sciences business intelligence firm Cutting Edge Information offers customized consulting and a growing library of targeted and insightful primary/secondary research reports that its competition cannot. Executives at more than 400 pharmaceutical and biotech firms have used Cutting Edge Information’s comprehensive, original pharmaceutical and benchmarking data and consulting services to make critical decisions on issues of both strategy and tactics.

 

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.

 

Venue

Waerwick Geneva 14 Rue De Lausanne Gent, GE1201, Schweiz, 0445118477 Zu einheitlichen Tarifen

4* luxury venue The Cumberland.  The location is central, just adjacent to Oxford Street Europe's busiest shopping street, and as of 2011 had approximately 300 shops and Hyde Park one of the largest parks in London, and one of the Royal Parks of London, famous for its Speakers' Corner.

http://www.guoman.com/en/hotels/united_kingdom/london/the_cumberland/index.html

Phone:
0207 074 8900

Email:
info@appelconsulting.co.uk

Accommodation is included in the registration fee. However, there is limited availability so we do encourage attendees to book early to avoid disappointment. 

Please click below for virtual tour for hotel

www.guoman.com/virtual_tour/the_cumberland/index.htm

Book Now

We accept credit card and debit card payments please process payment online to register for our events.

Please note that for all sponsorship packages we accept payment via bank transfer.

All discounts such as super early bird disocunts and early bird discounts we accept payment via bank transfer.

For more information please kindly email info@appelconsulting.co.uk